Dataset Information

Genetic testing for misclassified monogenic diabetes in Maori and Pacific peoples in Aotearoa New Zealand with early-onset type 2 diabetes.

ABSTRACT:

Aims

Monogenic diabetes accounts for 1-2% of diabetes cases yet is often misdiagnosed as type 2 diabetes. The aim of this study was to examine in Māori and Pacific adults clinically diagnosed with type 2 diabetes within 40 years of age, (a) the prevalence of monogenic diabetes in this population (b) the prevalence of beta-cell autoantibodies and (c) the pre-test probability of monogenic diabetes.

Methods

Targeted sequencing data of 38 known monogenic diabetes genes was analyzed in 199 Māori and Pacific peoples with BMI of 37.9 ± 8.6 kg/m² who had been diagnosed with type 2 diabetes between 3 and 40 years of age. A triple-screen combined autoantibody assay was used to test for GAD, IA-2, and ZnT8. MODY probability calculator score was generated in those with sufficient clinical information (55/199).

Results

No genetic variants curated as likely pathogenic or pathogenic were found. One individual (1/199) tested positive for GAD/IA-2/ZnT8 antibodies. The pre-test probability of monogenic diabetes was calculated in 55 individuals with 17/55 (31%) scoring above the 20% threshold considered for diagnostic testing referral.

Discussion

Our findings suggest that monogenic diabetes is rare in Māori and Pacific people with clinical age, and the MODY probability calculator likely overestimates the likelihood of a monogenic cause for diabetes in this population.

SUBMITTER: Toomata Z

PROVIDER: S-EPMC10206310 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genetic testing for misclassified monogenic diabetes in Māori and Pacific peoples in Aōtearoa New Zealand with early-onset type 2 diabetes.

Toomata Zanetta Z Leask Megan M Krishnan Mohanraj M Cadzow Murray M Dalbeth Nicola N Stamp Lisa K LK de Zoysa Janak J Merriman Tony T Wilcox Phillip P Dewes Ofa O Murphy Rinki R

Frontiers in endocrinology 20230510

<h4>Aims</h4>Monogenic diabetes accounts for 1-2% of diabetes cases yet is often misdiagnosed as type 2 diabetes. The aim of this study was to examine in Māori and Pacific adults clinically diagnosed with type 2 diabetes within 40 years of age, (a) the prevalence of monogenic diabetes in this population (b) the prevalence of beta-cell autoantibodies and (c) the pre-test probability of monogenic diabetes.<h4>Methods</h4>Targeted sequencing data of 38 known monogenic diabetes genes was analyzed in ...[more]

PMID: 37234800

Similar Datasets

Project description:ObjectivesTo explore the perspectives of Māori and Pacific women who participated in the Fish Oil study to ascertain what barriers and facilitators may exist for successfully recruiting Māori and Pacific women into clinical trials.DesignA Kaupapa Māori qualitative study.SettingAuckland, New Zealand.Participants16 Māori and Pacific women who participated in the fish oil supplementation during pregnancy study (ACTRN12617001078347p) between 1 January 2017 and 31 December 2020.Main outcome measuresSemistructured in-depth interviews were conducted, recorded and transcribed and then subjected to inductive thematic analysis to identify key themes related to barriers and facilitators of successful Māori and Pacific women recruitment into a clinical trial.ResultsOf 37 eligible Māori and Pacific women who participated in the original Fish Oil study, 16 women consented to participate in this study. Three key themes were identified: (1) relationships matter, (2) privileges and barriers and (3) the study experience. Key facilitators for recruitment included having solid relationships with research team members, practising exemplary professionalism, having clear communication and having the ability to establish rapport and research team flexibility. The desire to create a better future for participants' babies and to give back to Māori and Pacific communities through participating in a clinical trial were also key drivers of successful recruitment. In contrast, the major barriers described were time pressures and the distance to the research facility.ConclusionsSixteen Māori and Pacific women who participated in a double-blinded randomised controlled trial shared that successful recruitment of Māori and Pacific women into clinical trials can be promoted by research flexibility participants' whānau/family responsibilities, effective and culturally safe communication, and research teams striving to build and maintain relationships with participants throughout the trial.Trial registeration numberAustralian New Zealand Clinical Trials Registry, ACTRN12617001078347p. Universal Trial Number (U1111-1199-5860).

Project description:BackgroundThe Census of Populations and Dwellings' is the five yearly population count of Aotearoa New Zealand. Best available populations (BAP) are subnational projections based on census data and demographic assumptions developed for healthcare planning and funding allocation but are also used as the denominator for health indicator monitoring. Pacific people are systematically undercounted, but the impact on health statistics is not well studied. For COVID-19 vaccination coverage, health service user (HSU) data were considered a more reliable denominator than BAP but introduced new biases. We aimed to understand how the choice of denominator population impacts estimates of population size and health system performance for Pacific people at a local level.MethodsWe described how declining census response rates affected population data quality. We compared BAP and HSU data at district level. For the indicators 'access to primary care' and 'cervical cancer screening uptake' we replaced currently used BAP denominators with HSU and examined the impact for different ethnic groups in different geographic districts.ResultsOverall Census 2018 response declined by 10%, but for Māori and Pacific people by 21% and 23%, respectively. This inequitably affected BAP accuracy. Census undercount was highest in the district with the largest Pacific populations, where HSU exceeded BAP most. Notably, 'access to primary care' for Pacific people in this district consistently exceeds 100%. Using BAP, both health indicators are currently estimated as highest for Pacific people compared to other ethnic groups, but when based on HSU, they dropped to lowest. Similar, but less pronounced trends occurred in other districts. Changes in trends over time for both indicators coincided mostly with adjustments in BAP, rather than changes in the numerators.ConclusionsThe current use of BAP denominators for health statistics does not enable reliable monitoring of key health indicators for Pacific people. HSU denominators are also unsuitable for monitoring health. Exploring the feasibility of a real-time population register is strongly recommended as a new, transparent, way of obtaining more reliable, timely population data to guide policymaking and underpin a more equitable health system under the health reforms. Meanwhile, reporting of ethnic specific outcomes need to include a clear assessment of the potential for bias due to inaccurate population estimates.